







UNDER DEVELOPMENT

ACTIVE PHARMACEUTICAL INGREDIENT	REFERENCE PRODUCT	INDICATION	DMF READINESS
 Ivacaftor	Kalydeco® Vertex	Cystic fibrosis	DMF Q4 2024
Opicapone	Ongentys® Bial and Neurocrine Biosciences	“Off” episodes in Parkinson	DMF Q1 2024
Relugolix	Orgovyx®, Myfembree® (US) / RYEQO (EU), Myovant Sciences	Prostate cancer and uterine fibroid bleeding Pain associated with endometriosis	DMF Q2 2024
 Ruxolitinib hemifumarate	Jakavi®, Novartis	Myelofibrosis, polycythemia vera and graft-versus-host-disease	DMF Q2 2024
 Ruxolitinib phosphate	Jakafi®, Novartis	Myelofibrosis, polycythemia vera Graft-versus-host-disease	DMF Q2 2025
Tezacaftor	Symdeko® (US) and Symkevi® (EU) Vertex	Cystic fibrosis	DMF Q1 2027
 Voclosporin	Lupkynis® Aurinia Pharmaceuticals and Otsuka Pharmaceutical	Lupus Nephritis	DMF Q2 2024